Multiple Sclerosis (MS) is an autoimmune demyelinating disease affecting mainly the young population and resulting to different levels of disability. Different mechanisms of inflammation-demyelination, axonal damage-neurodegeneration, gliosis, and remyelination-repair, combine together in various degrees reflecting the complicated pathophysiology and the great variety of clinical course among patients. This variability of pathophysiology and clinical course leads to different levels of response to treatments. Several biomarkers are used today in addition to the clinical course and the imaging, to estimate the prognosis of MS and objectively evaluate the efficacy of treatments. Taking in account the different mechanisms that are prominent in each individual patient with MS such biomarkers are essential to idendify the best candidates for each immunotherapy and the best responders to each modality, in order to develop tolls for personalization/tailoring of the treatment to each individual. Several recent trials indicate a possible predictive value of certain biomarkers, such as the anti-MOG antibodies, CXCL13 and Neurofilaments, on the prognosis of the course of MS. These data will be summarized in my talk.